UntilLabs

UntilLabs

Advances reversible organ cryopreservation technology

Overview

UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.

Significant Headcount Growth

About UntilLabs

Simplify's Rating
Why UntilLabs is rated
C+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

San Francisco, California

Founded

2024

Get referred to UntilLabs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Until Labs raised $58M on 2025-09-22 from Founders Fund, Lux, and Field Ventures.
  • Its 2026 careers page shows aggressive hiring across biology, engineering, legal, and operations.
  • The roadmap targets kidney, liver, heart validation and GLP studies for first-in-human trials.

What critics are saying

  • Organ cryopreservation remains scientifically unproven for human transplantation by 2026.
  • The 2025-09-22 Series A still funds research, not clinical product revenue.
  • Failure in large-animal organs before 2027 kills its transplant and hibernation thesis.

What makes UntilLabs unique

  • Until Labs combines organ perfusion, cryoprotectants, cooling, and rewarming hardware.
  • Its organ-scale focus directly targets transplant logistics, not distant whole-body speculation.
  • The 2026 alternating magnetic-field rewarming blog shows real engineering depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Commuter Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

14%

1 year growth

14%

2 year growth

22%
Pioneer Publishers
Sep 22nd, 2025
Until Labs Secures $58M for Cryopreservation

Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.

Fenwick & West
Sep 22nd, 2025
Fenwick Represents Until Labs in $58M Series A Funding

Fenwick represents Until Labs in $58M Series A funding.

Recently Posted Jobs

Sign up to get curated job recommendations

UntilLabs is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →